Anika Therapeutics, Inc. — Q1 2015 Form 10-Q Summary
Business context and reporting period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair across orthobiologics, dermal, surgical, ophthalmic, and veterinary markets. The filing covers the three months ended March 31, 2015, compared with the same period in 2014. The financial statements are unaudited and prepared under U.S. GAAP.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $15.5 million | $34.0 million | Down 54% |
| Product revenue | $15.5 million | $14.4 million | Up 8% |
| Licensing, milestone and contract revenue | $5,642 | $19.7 million | Down approximately 100% |
| Income from operations | $5.5 million | $23.9 million | Down 77% |
| Net income | $3.5 million | $15.0 million | Down 77% |
| Diluted EPS | $0.23 | $0.97 | Down $0.74 |
| Operating cash flow | $4.0 million | $13.6 million | Down 71% |
Product gross profit increased 12% to $11.2 million, and product gross margin improved to 72% from 70%, primarily because of a more favorable product mix. Based on total revenue, the operating margin was approximately 35% versus 70% in the prior-year quarter, while the net margin was approximately 23% versus 44%.
At March 31, 2015, cash and cash equivalents were $99.8 million, investments were $12.5 million, and total cash, cash equivalents, and investments were approximately $112.3 million. Working capital was approximately $139.8 million. The balance sheet does not show outstanding borrowings or debt; the filing text does not provide a separate debt covenant discussion.
Total assets were $197.7 million and stockholders’ equity was $181.8 million. Accounts receivable declined to $16.0 million from $17.2 million at year-end 2014, while inventory was broadly stable at $12.5 million. Cash declined by $0.4 million during the quarter after $6.0 million of investing outflows, including $7.25 million of investment purchases.
Material changes versus the prior comparable period
- Product revenue increased $1.2 million, led by Orthobiologics, Dermal, Ophthalmic, and Veterinary products; Surgical revenue declined because of distributor order timing.
- Total revenue and earnings fell sharply because Q1 2014 included approximately $19.7 million of MONOVISC-related licensing and milestone revenue, including a $17.5 million milestone and approximately $2.2 million of previously deferred revenue.
- Research and development expense decreased 8% to $2.1 million because Q1 2014 included higher CINGAL pivotal-trial activity. Management expects research and development spending to increase as additional trials begin.
- SG&A expense increased 3% to $3.6 million, primarily due to personnel-related costs, stock-based compensation, and professional fees.
- Operating cash flow decreased primarily because of the lower reported net income and the absence of the prior-year MONOVISC milestone proceeds.
- Foreign currency translation reduced other comprehensive income by $2.25 million and reduced goodwill by approximately $0.9 million during the quarter.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects Orthobiologics revenue to grow in 2015, supported by increased U.S. MONOVISC revenue and international viscosupplementation sales.
- Advanced wound-care revenue is expected to increase, particularly from geographic expansion following the Medline agreement for HYALOMATRIX.
- Surgical revenue is expected to remain similar to 2014 for the full year, while Ophthalmic revenue is expected to decline following the expected expiration of the Bausch & Lomb AMVISC supply agreement.
- Veterinary revenue is expected to increase because of higher U.S. demand. No quantitative full-year revenue or earnings guidance was provided.
- HYALOSPINE received CE Mark approval in January 2015, resulting in the reclassification of $400,000 from in-process research and development to developed technology and the start of amortization.
- Anika submitted an FDA Investigational Device Exemption for HYALOFAST in Q1 2015 and planned to begin a Phase III trial in the second half of 2015. The company also submitted a U.S. premarket application for CINGAL in February 2015 and expects CINGAL retreatment-study safety data in Q3 2015.
- Management believes available cash and investments are sufficient to support operations for at least the next twelve months. Future cash needs may increase with business expansion and clinical development; additional financing could be required if internal resources are insufficient.
- Key risks include regulatory approvals, clinical and product-development outcomes, competition, supply interruptions, product quality, pricing pressure, intellectual-property protection, healthcare-policy changes, international operations, and dependence on key personnel.
- The company reported no material changes to previously disclosed risk factors, no material changes to contractual obligations, and no material adverse legal proceedings. It reported no accrued product warranties and no history of warranty claims paid.
- Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Assess recurring product revenue and profitability separately from the nonrecurring MONOVISC milestones recognized in 2014.
- Track U.S. MONOVISC sales, reimbursement developments, and the economic impact of the Mitek licensing agreement.
- Verify the timing, cost, and regulatory status of the HYALOFAST Phase III program and CINGAL applications.
- Monitor foreign-exchange effects on European operations, goodwill, intangible assets, and comprehensive income.
- Confirm the absence of funded debt and review future liquidity needs associated with clinical trials, commercialization, and potential expansion.
- Evaluate whether the 72% product gross margin is sustainable, since management cautioned that quarterly product mix may cause future margins to vary.